Berta Anuncibay-Soto Selected Research

Ischemia

9/2023	Neuroprotective effects of meloxicam on transient brain ischemia in rats: the two faces of anti-inflammatory treatments.
4/2021	Celecoxib-Dependent Neuroprotection in a Rat Model of Transient Middle Cerebral Artery Occlusion (tMCAO) Involves Modifications in Unfolded Protein Response (UPR) and Proteasome.
12/2019	Post-ischemic salubrinal administration reduces necroptosis in a rat model of global cerebral ischemia.
1/2019	Brain-derived neurotrophic factor alleviates the oxidative stress induced by oxygen and glucose deprivation in an ex vivo brain slice model.
12/2018	Celecoxib Treatment Improves Neurologic Deficit and Reduces Selective Neuronal Loss and Glial Response in Rats after Transient Middle Cerebral Artery Occlusion.
1/2018	Salubrinal and robenacoxib treatment after global cerebral ischemia. Exploring the interactions between ER stress and inflammation.
1/2016	Post-ischemic salubrinal treatment results in a neuroprotective role in global cerebral ischemia.
1/2014	Age-dependent modifications in vascular adhesion molecules and apoptosis after 48-h reperfusion in a rat global cerebral ischemia model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Berta Anuncibay-Soto Research Topics

Disease

8	Ischemia 09/2023 - 01/2014
5	Stroke (Strokes) 09/2023 - 01/2018
5	Brain Ischemia (Cerebral Ischemia) 09/2023 - 01/2016
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 04/2021 - 12/2018
2	Ischemic Stroke 04/2021 - 12/2018
1	Inflammation (Inflammations) 09/2023
1	Gliosis 09/2023
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022
1	Sleep Deprivation 01/2022
1	Neurologic Manifestations (Neurological Manifestations) 12/2018
1	Infarction (Infarctions) 12/2018

Drug/Important Bio-Agent (IBA)

4	salubrinalIBA 12/2019 - 01/2016
3	Neuroprotective AgentsIBA 09/2023 - 01/2016
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 09/2023 - 01/2018
2	CalciumIBA 01/2022 - 12/2018
2	Proteins (Proteins, Gene)FDA Link 04/2021 - 01/2018
2	Celecoxib (Celebrex)FDA Link 04/2021 - 12/2018
2	Cell Adhesion MoleculesIBA 01/2018 - 01/2014
1	Protein Isoforms (Isoforms)IBA 09/2023
1	Meloxicam (Mobic)FDA LinkGeneric 09/2023
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 09/2023
1	N-Methylaspartate (NMDA)IBA 01/2022
1	Zolpidem (Ambien)FDA LinkGeneric 01/2022
1	Hypnotics and Sedatives (Sedatives)IBA 01/2022
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2022
1	Dexmedetomidine FDA Link 01/2022
1	Proteasome Endopeptidase Complex (Proteasome)IBA 04/2021
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2021
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 12/2019
1	Messenger RNA (mRNA)IBA 12/2019
1	Phosphotransferases (Kinase)IBA 12/2019
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2019
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 12/2018
1	robenacoxibIBA 01/2018
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2018
1	E-SelectinIBA 01/2014
1	Glial Fibrillary Acidic ProteinIBA 01/2014
1	Caspase 3 (Caspase-3)IBA 01/2014
1	P-SelectinIBA 01/2014

Therapy/Procedure

4	Therapeutics 04/2021 - 01/2018